NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) —
BioMarin Pharmaceutical Inc. (NASDAQGS: BMRN)
Lifshitz Law PLLC
announces that a class action complaint was filed on behalf of shareholders of BioMarin alleging that Defendants made false and/or misleading statements and/or failed to disclose that: (i) BMN 307 was less safe than BioMarin had led investors to believe; (ii) BMN 307’s safety profile made it likely that the FDA would place a clinical hold on the Phearless Phase 1/2 study; (iii) accordingly, the Company had overstated BMN 307’s clinical and commercial prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you are a BioMarin investor, and would like additional information about our investigation, please complete the
Information Request Form
or contact
Joshua Lifshitz, Esq.
by telephone at (516)493-9780 or e-mail at
[email protected]
.
On24, Inc. (NYSE: ONTF)
Lifshitz Law PLLC
announces that a class action complaint was filed against ONTF alleging that representations made in the registration statement and prospectus used to effectuate the ONTF’s IPO were materially inaccurate, misleading, and/or incomplete because they failed to disclose, among other things, that the surge in COVID-19 customers observed in the lead up to the IPO consisted of a significant number that did not fit ONTF’s traditional customer profile, and, as a result, were significantly less likely to renew their contracts.
If you are a ONTF investor, and would like additional information about our investigation, please complete the
Information Request Form
or contact
Joshua Lifshitz, Esq.
by telephone at (516)493-9780 or e-mail at
[email protected]
.
Silverback Therapeutics, Inc. (NASDAQ: SBTX)
Lifshitz Law PLLC
announces that a class action complaint has been filed against Silverback alleging that the Offering Documents and Defendants made false and/or misleading statements and/or failed to disclose that: (i) Silverback’s lead product candidate SBT6050 was less effective than the Company had represented to investors; (ii) accordingly, the Company had overstated SBT6050’s commercial and/or clinical prospects; and (iii) as a result, the Offering Documents and Defendants’ public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein.
If you are an Silverback investor, and would like additional information about our investigation, please complete the
Information Request Form
or contact
Joshua Lifshitz, Esq.
by telephone at (516)493-9780 or e-mail at
[email protected]
.
Selectquote, Inc. (NYSE: SLQT)
Lifshitz Law PLLC
announces that a class action complaint was filed against SLQT alleging that Defendants made material misrepresentations concerning the following: (1) that SelectQuote’s 2019 cohort was underperforming; (2) that, as a result, the Company’s financial results would be adversely impacted; and (3) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you are an SLQT investor, and would like additional information about our investigation, please complete the
Information Request Form
or contact
Joshua Lifshitz, Esq.
by telephone at (516)493-9780 or e-mail at
[email protected]
.
ATTORNEY ADVERTISING.
© 2022 Lifshitz Law PLLC The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact:
Joshua M. Lifshitz, Esq.
Lifshitz Law PLLC
Phone: 516-493-9780
Facsimile: 516-280-7376
Email:
[email protected]
